FDA 483 - Winder Laboratories, LLC - August 05, 2025

Winder Laboratories, LLC received a Form 483 with numerous significant observations related to its drug manufacturing operations. Key issues include quality control unit failures, premature product release, inadequate stability testing, lack of process validation, and widespread deficiencies in cleaning, equipment maintenance, and documentation practices. These findings indicate a systemic lack of adherence to cGMP regulations, posing potential risks to drug product quality, safety, and efficacy.